Anika T Thomas-Toth
Overview
Explore the profile of Anika T Thomas-Toth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liao R, Hsu J, Aboelella N, McKeever J, Thomas-Toth A, Koh A, et al.
Cancer Immunol Res
. 2024 May;
12(8):1074-1089.
PMID: 38810242
The specific BCL-2 small molecule inhibitor venetoclax induces apoptosis in a wide range of malignancies, which has led to rapid clinical expansion in its use alone and in combination with...
2.
Schnorenberg M, Hawley K, Thomas-Toth A, Watkins E, Tian Y, Ting J, et al.
ACS Nano
. 2023 Sep;
17(23):23374-23390.
PMID: 37688780
Diffuse large B-cell lymphoma (DLBCL) remains a formidable diagnosis in need of new treatment paradigms. In this work, we elucidated an opportunity for therapeutic synergy in DLBCL by reactivating tumor...
3.
Hawley K, Eclov R, Schnorenberg M, Tian Y, Shah R, Thomas-Toth A, et al.
Proc Natl Acad Sci U S A
. 2022 Oct;
119(42):e2209044119.
PMID: 36227917
Despite continuing advances in the development of novel cellular-, antibody-, and chemotherapeutic-based strategies to enhance immune reactivity, the presence of regulatory T cells (Treg cells) remains a complicating factor for...
4.
Ludwig L, Hawley K, Banks D, Thomas-Toth A, Blazar B, McNerney M, et al.
Cell Death Dis
. 2021 Oct;
12(11):1005.
PMID: 34707089
BH3 mimetics are increasingly used as anti-cancer therapeutics either alone or in conjunction with other chemotherapies. However, mounting evidence has also demonstrated that BH3 mimetics modulate varied amounts of apoptotic...